Because treatments that meaningfully slow or halt the progression of some subtypes of amyloidosis have been available for more than 5 years, a missed diagnosis has become a serious issue. And an ...

I, and any amyloid provider, can probably personally attest to the difference in clinical course when you treat a patient who is detected to have this disease early compared to late, and we’d ...

Dialysis patients often develop dialysis-related amyloidosis and exhibit bone and joint disorders that impair their activity of daily living. Blood purification devices consisting of hexadecyl ...

AL amyloidosis is diagnosed in as many as 10 to 15% of patients with myeloma, and 38% of patients with myeloma have Congo red–positive deposits in subcutaneous fat aspirates, bone marrow ...

Annals of the Rheumatic Diseases Source Reference: Kvacskay P, et al "bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease" Ann Rheum Dis 2024; DOI: 10.1136/ard-2023-225114.

bDMARD therapy preserved renal function in 75% of patients with AA amyloidosis, but the remaining 25% progressed to ESRD despite receiving bDMARD therapy.

In this phase 3, double-blind, randomized trial, we assigned patients with hereditary, also known as variant, or wild-type ATTR cardiac amyloidosis, in a 1:1 ratio, to receive patisiran (0.3 mg ...